National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)

The NCCN‑IPI is a refined prognostic score for DLBCL that uses age, LDH, stage, extranodal sites, and performance status to stratify survival risk more accurately in the rituximab era.

Age, years
≤ 40041-60+161-75+2> 75+3
LDH ratio
≤ 10> 1-3+1> 3+2
ECOG Performance Status ≥ 2
No0Yes+1
Ann Arbor stages III or IV
No0Yes+1
> 1 extranodal disease site (disease in BM, CNS, liver/GIT or lungs)
No0Yes+1

Indications for Use

Used in newly diagnosed diffuse large B‑cell lymphoma to stratify survival risk and guide intensity of frontline management. Provides finer discrimination of low‑ vs high‑risk groups (5‑yr OS 96% vs 33%) than IPI using age, LDH, stage, extranodal sites, and ECOG (Blood 2014 1 [Level II evidence]; Blood 2020 2 [Level II evidence]). Useful for baseline prognosis and clinical‑trial stratification; not a treatment decision tool.

Insights & Cautions

Better discriminates survival than older indices but still has limits: strongest separation of low vs high risk in large DLBCL cohorts (5‑year OS ~96% vs 33%) 1 [Level II evidence].
• Underestimates risk in molecular high‑risk disease; no subgroup consistently <50% long‑term survival in modern series 2 [Level I evidence].
• Performance depends on accurate extranodal assessment; PET/CT can upstage ~18% and alter risk group assignment 3 [Level II evidence].
• Does not incorporate tumor genetics or PET radiomics, which outperform clinical scoring 4 [Level II evidence].